Fig. 2
From: Antisecretory factor is safe to use as add-on treatment in newly diagnosed glioblastoma
Contrast enhanced MRI studies of one patient (#5) a before surgery, b postoperatively, c after completed Salovum therapy, d at 12-month follow-up, e at 18-month follow-up and f at 24-month follow-up. This patient displayed increased contrast enhancement after the concomitant therapy followed by diminishing enhancement and durable tumor control, possibly due to initial radionecrosis followed by delayed immunologic response to therapy